A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
Status:
Terminated
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies how well two donors stem cell transplant work in
treating patients with high-risk hematologic malignancies. After receiving radiation to help
further treat the disease, patients receive a dose of donors' T cells. T cells can fight
infection and react against cancer cells. Two days after donors' T cells are given, patients
receive cyclophosphamide (CY) to help destroy the most active T cells that may cause tissue
damage (called graft versus host disease or GVHD). Some of the less reactive T cells are not
destroyed by CY and they remain in the patient to help fight infection. A few days after the
CY is given, patients receive donors' stem cells to help their blood counts recover. Using
two donors' stem cell transplant instead of one donor may be more effective in treating
patients with high-risk disease and may prevent the disease from coming back.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University